Working the aromatase-inhibitor case in time order

Return to the opening case: a postmenopausal patient started on aromatase-inhibitor therapy for breast cancer treatment, an oncology context where estradiol monitoring supports confirming adequate estrogen suppression, not directing dose. Pretreatment estradiol by immunoassay was 30 pg/mL, already low for a postmenopausal baseline but above the assay's limit of quantitation of 25 pg/mL, so that number can be trusted at roughly its face value.

At week 4, the immunoassay produced a 22 pg/mL raw signal, reported with the validated below-LoQ qualifier, now below the limit of quantitation. This is consistent with a real drop, but a result below the limit of quantitation carries more imprecision than the same platform's result above it, so the true value could be meaningfully lower or, less likely, close to what was reported. At week 12, the immunoassay signal is 21 pg/mL, again below LoQ and reported with the validated qualifier; it cannot establish a plateau.

The laboratory sent the week 12 specimen for LC-MS/MS confirmation. It measured 6 pg/mL, above the immunoassay 5 pg/mL LoD and below its 25 pg/mL LoQ. It is an LC-MS/MS result, so whether it is quantifiable follows the LC-MS/MS method's own reporting rule, not immunoassay limits. The immunoassay's 21 pg/mL was not a precise measurement of a stable 21 pg/mL; it was a value pulled upward, likely by cross-reacting estrogen metabolites, once true estradiol fell below the region the assay can reliably resolve.

The defensible laboratory interpretation is not that the drug failed and not that suppression is confirmed adequate by the immunoassay number. It is narrower: the immunoassay trend from week 4 onward is not reliable evidence of the true estradiol trajectory, and the LC-MS/MS result of 6 pg/mL is the more trustworthy value for this specimen. Whether 6 pg/mL represents adequate suppression for this patient's treatment goal is a clinical judgment outside laboratory scope; the laboratory's job is to report the more specific, more defensible number and say plainly why the immunoassay trend should not be read as reassuring on its own. When a low-range trend stops making analytical sense, question the method before questioning the physiology.